PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of April 16, 2024, PODD stock price declined to $172.71 with 584,022 million shares trading.

PODD has a beta of 1.84, meaning it tends to be more sensitive to market movements. PODD has a correlation of 0.20 to the broad based SPY ETF.

PODD has a market cap of $12.08 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $510 million in Revenue and $1.40 earnings per share. This beat revenue expectation by $49 million and exceeded earnings estimates by $.74.

In the last 3 years, PODD stock traded as high as $335.91 and as low as $125.82.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, VB, SPY, VO.

PODD has underperformed the market in the last year with a return of -45.8%, while the SPY ETF gained +23.7%. In the last 3 month period, PODD fell short of the market, returning -13.9%, while SPY returned +6.0%. However, in the most recent 2 weeks PODD has outperformed the stock market by returning +2.7%, while SPY returned -3.6%.

PODD support price is $170.11 and resistance is $177.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD stock will trade within this expected range on the day.